Table 2 Relationship between clinicopathological factors and 2D:4D values.
No. (%) | R2D:4D (s. d.) | P value | L2D:4D (s. d.) | P value | |
|---|---|---|---|---|---|
Overall | 382(100) | 0.949 (0.041) | 0.955 (0.045) | ||
Age/yr | 0.132 | 0.117 | |||
<65 | 68(17.8) | 0.953 (0.049) | 0.955 (0.045) | ||
65–75 | 217(56.8) | 0.949 (0.046) | 0.948 (0.041) | ||
>75 | 97(25.4) | 0.948 (0.044) | 0.957 (0.052) | ||
Pathological Gleason score | 0.294 | 0.355 | |||
<6 | 73(19.1) | 0.952 (0.038) | 0.955 (0.051) | ||
7 | 162(42.4) | 0.949 (0.055) | 0.957 (0.055) | ||
8–10 | 147(38.5) | 0.946 (0.050) | 0.948(0.045) | ||
Initial PSA (ng./ml.) | 0.420 | 0.324 | |||
<20 | 57(14.9) | 0.944 (0.041) | 0.960 (0.044) | ||
20–99.9 | 143(37.4) | 0.950 (0.046) | 0.951 (0.052) | ||
100–1000 | 158(41.4) | 0.951 (0.040) | 0.957 (0.053) | ||
>1000 | 24(6.3) | 0.947 (0.047) | 0.955 (0.040) | ||
PSA at 3 month (ng./ml.) | |||||
<4 | 167(45.3) | 0.955 (0.060) | 0.039 | 0.958 (0.055) | 0.046 |
≥4 | 202(54.7) | 0.944 (0.052) | 0.951 (0.043) | ||
PSA at 6 month (ng./ml.) | |||||
<4 | 195(57.0) | 0.957 (0.056) | 0.001 | 0.963 (0.045) | 0.001 |
≥4 | 147(43.0) | 0.939 (0.063) | 0.945 (0.055) | ||
Bone metastasis | 0.524 | 0.386 | |||
yes | 248 (64.9) | 0.950 (0.036) | 0.957 (0.053) | ||
no | 134 | 0.948 (0.037) | 0.952 (0.052) | ||
Lymph node metastasis | 0.072 | 0.129 | |||
yes | 115 (30.1) | 0.953 (0.056) | 0.956 (0.051) | ||
no | 267 (69.9) | 0.944 (0.053) | 0.955 (0.044) | ||
Lung metastasis | 0.861 | 0.520 | |||
yes | 21 (5.5) | 0.945(0.060) | 0.960 (0.057) | ||
no | 361 (94.5) | 0.950 (0.039) | 0.954(0.042) | ||
Pathological tumor stage | 0.202 | 0.334 | |||
TX, T0, T1 | 32 (5.8) | 0.953 (0.036) | 0.960 (0.039) | ||
T2 | 129 (33.8) | 0.949 (0.055) | 0.953 (0.046) | ||
T3 | 122 (34.6) | 0.946 (0.057) | 0.958 (0.045) | ||
T4 | 99 (25.9) | 0.948 (0.048) | 0.954 (0.039) | ||
No. therapy (%) | 0.290 | 0.481 | |||
Monotherapy3sd | 45 (11.8) | 0.962 (0.044) | 0.952 (0.060) | ||
combined | 337 (88.2) | 0.949 (0.040) | 0.956 (0.038) | ||
